Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

French, Prospective, Post-marketing Study to Describe the Use, Detection Performance and Safety Profile of Infracyanine® (Indocyanine Green) for Breast Cancer Patients Undergoing a Sentinel Lymph Node (SLN) Biopsy.

NCT06024213 is registered in ClinicalTrials.gov with BTG International Inc. as lead sponsor.

NCT NCT06024213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
French, Prospective, Post-marketing Study to Describe the Use, Detection Performance and Safety Profile of Infracyanine® (Indocyanine Green) for Breast Cancer Patients Undergoing a Sentinel Lymph Node (SLN) Biopsy.
Lead sponsor
BTG International Inc.
Phase
Observational
Overall status
Completed
Start date
June 6, 2023
Completion date
December 19, 2023
Enrollment
101 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer